Novel Therapeutics for Sepsis

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$155,180.00
Award Year:
2011
Program:
SBIR
Phase:
Phase I
Contract:
1R43AI092874-01
Agency Tracking Number:
R43AI092874
Solicitation Year:
2011
Solicitation Topic Code:
NIAID
Solicitation Number:
PA10-050
Small Business Information
ONCOIMMUNE, INC.
12111 Parklawn Drive, Suite 105, Rockville, MD, 20852
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
146678516
Principal Investigator:
DEXING FANG
(734) 332-4234
dfang@oncoimmune.com
Business Contact:
LI XU
(614) 340-1686
lxu@oncoimmune.com
Research Institution:
Stub




Abstract
DESCRIPTION (provided by applicant): Sepsis is one of the top leading causes of deaths for Americans and it is responsible for approximately 200,000 deaths in US annually. Despite of the advance of antibiotics and medical treatment in general, there has been no reduction in severity and death associated with the disease. Since inflammation is the underlying cause of sepsis, the lack of progress in sepsis treatment suggests major gaps in understanding the root cause of inflammation associated with infection.A major breakthrough in immunology is the identification of pathogen-associated molecular pattern (PAMP) as the root cause of inflammation. However, PAMP alone does not explain sepsis as controlling infection, which should remove PAMP, is insufficient tocure sepsis. Another source of inflammation is tissue damage-associated molecular pattern (DAMP). We have recently demonstrated that host response to DAMP is controlled by CD24-Siglec 10/G interaction. Our preliminary data provided herein demonstrated thatsepsis is associated with disruption of CD24-Siglec 10 interaction and polybacterial sepsis in the mouse can be effectively treated by sialidase inhibitors. Here we propose to use rational drug design and a novel enzymo-chemical synthesis strategy to produce sialidase inhibitors for the treatment of sepsis, as detailed in two specific aims. Specifically, we will produce new sialidase inhibitors through the rational drug design and our novel enzymochemical strategy. Then we will use cecal ligation and puncture (CLP) model to test the therapeutic efficacy of the novel sialidase inhibitors. As proof of concept, the successful completion of this proposal will not only sustain bacterial sialidase as the therapeutic target for sepsis, but also provide new and effective prototype drugs for further development. PUBLIC HEALTH RELEVANCE: Sepsis is the tenth leading cause of deaths for Americans as it is responsible for approximately 200,000 deaths in US annually. Despite of the advance of antibiotics and medical treatment in general, there has been no reduction in severity and death associated with the disease. The ultimate goal of this application is to develop a novel and effective treatment for sepsis by targeting on the bacterial sialidase.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government